LAWRENCE, KS - Clara Biotech, Inc., a spinout from the University of Kansas, announced today the introduction of its first laboratory research product, the ExoReleaseTM Starter Kit. This technological breakthrough captures extracellular vesicles (EVs) and exosomes using immuno-affinity and releases them using a photo-cleavable linker. The ExoRelease Starter Kit incorporates Clara’s established ExoReleaseTM Exosome Capture and Release Platform, which provides a simple, reproducible, and time-saving protocol that yields pure, completely functional, in-tact, and subtyped exosomes. This protocol allows the isolation and purification of exosomes/EVs from multiple bio-sample types, including plasma, cell culture media, urine, saliva, and others, without other nanoparticle contaminants.
The introduction of the ExoRelease Starter Kit is a significant milestone that marks an expansion in Clara’s capabilities to assist researchers as they pursue basic scientific questions, investigate new biomarkers and diagnostic applications, and explore and refine exosome-based therapeutics. Prior to developing this product, Clara utilized the ExoRelease platform in a variety of exosome isolation and downstream analyses through contract research services. The ExoRelease Starter Kit, which is scheduled for launch in the coming months, brings the ExoRelease technology directly to biopharma labs, diagnostic and academic partners, and customers. The process can be easily integrated into standard workflows and processes, isolating and purifying exosomes based on surface markers on the exosomes’ bilipid membrane.
Clara Biotech’s ExoRelease platform is the only exosome system that provides both the capture and the release of pure exosomes from magnetic beads while effectively addressing one of the most pressing challenges in exosome/EV purification - the removal of impurities. The ExoRelease Starter Kit expands the reach of this sophisticated platform for purifying exosomes/EVs, which will ultimately accelerate and de-risk early product concepts enabling the next generation of diagnostics, biomarkers, and therapeutics.
For more information contact firstname.lastname@example.org.
About Clara Biotech
Clara Biotech was founded in 2018 by Dr. Mei He, exosome expert and assistant professor at the University of Florida, and James E West III, engineer, and entrepreneur. Clara Biotech licensed the technology for novel methods to isolate and purify exosomes from the University of Kansas. Its non-chemical ExoRelease™ platform uses proprietary immunocapture and release technology to exclusively isolate exosomes. The ExoRelease™ platform provides a simple, reproducible, time-saving protocol and has the same process for multiple bio-sample types. This yields pure, completely functional, in-tact, and subtyped exosomes. Clara Biotech is in the process of commercializing its ExoRelease™ Starter Kit for Research Use Only.